Mast Therapeuthicals MSTX - Buy
Seite 1 von 4 Neuester Beitrag: 26.06.24 13:33 | ||||
| Eröffnet am: | 23.03.15 15:18 | von: Barica Inves. | Anzahl Beiträge: | 90 |
| Neuester Beitrag: | 26.06.24 13:33 | von: Vassago | Leser gesamt: | 33.830 |
| Forum: | Hot-Stocks | Leser heute: | 15 | |
| Bewertet mit: |  | |||
| Seite: < 1 | 2 | 3 | 4 4 > | ||||
Heute positive Studiendaten:
http://www.nasdaq.com/press-release/...c-heart-failure-20150323-00305
Empfehlung vom Freitag: SEEKING ALPHA
http://seekingalpha.com/article/...t-opportunity-as-phase-iii-ongoing
Hier werde ich nach und nach Daten zu MSTX einstellen.
Ich denke wir gehen heute noch bis mindestens 0,53 Dollar.
Bernd.
Optionen
| Boardmail an "Barica Investments" |
Wertpapier: Savara |
113 Mio. $ Offering
- 45,8 Mio. neue Aktien zu 1,45$
- 32,2 Mio. "pre-funded warrants" zu je 1,449$
"Savara intends to use the net proceeds from this offering for working capital to support operations, including but not limited to clinical development, manufacturing, regulatory, and commercial activities related to its molgramostim nebulizer solution (molgramostim, formerly referred to as Molgradex) in autoimmune pulmonary alveolar proteinosis (aPAP) program and the IMPALA 2 trial, and general and administrative expenses."
https://savarapharma.com/investors/press-releases/release/?id=13106
Optionen
| Boardmail an "Vassago" |
Wertpapier: Savara |
Einige Insider haben sich offenbar an dem Offering beteiligt
Optionen
| Boardmail an "Vassago" |
Wertpapier: Savara |
Zahlen für Q3/21
- keine Umsätze
- Verlust 10,5 Mio. $
- Cash 171 Mio. $
- MK 120 Mio. $
- Company Believes it is Sufficiently Capitalized Through 2025, ~18 Months Beyond Anticipated IMPALA-2 Top-Line Data Readout at End of Q2 2024
https://savarapharma.com/investors/press-releases/release/?id=13651
Interessantes Kursniveau, geringer Cashburn
Optionen
| Boardmail an "Vassago" |
Wertpapier: Savara |
Zahlen für Q1/24
- kein Umsatz
- operativer Verlust 22 Mio. $
- Cash 143 Mio. $
- MK 546 Mio. $
- Pivotal Phase 3 IMPALA-2 Trial Remains On-track, Top Line Results Expected by End of 2Q 2024
- the Company Continues to Believe it is Sufficiently Capitalized into 2026
https://savarapharma.com/investors/press-releases/release/?id=14706
Optionen
| Boardmail an "Vassago" |
Wertpapier: Savara |
Optionen
| Boardmail an "Vassago" |
Wertpapier: Savara |
https://savarapharma.com/investors/press-releases/release/?id=14776
Optionen
| Boardmail an "Vassago" |
Wertpapier: Savara |